Perfluorocarbon Nanoemulsions For Combined Pulmonary Sirna Treatment Of Lung Metastatic Osteosarcoma

Zhaoting Li,Yuexin Shen,Yixin Wang,Lianghan Zhu,Chenfei Zhu,Chenggen Qian,Minjie Sun,David Oupicky
DOI: https://doi.org/10.1002/adtp.201900039
IF: 5.003
2019-01-01
Advanced Therapeutics
Abstract:Lung metastatic osteosarcoma is a lethal disease afflicting children and adolescents, with a 5-year survival rate of less than 20%. The development of perfluorocarbon (PFC) nanoemulsions as systems for direct pulmonary delivery of combination drug/siRNA therapy is reported. Fluorinated polycation (F-PCX) with an inherent ability to inhibit C-X-C receptor type 4 (CXCR4) is synthesized and used as a surfactant in the preparation of F-PCX@PFC nanoemulsions. The nanoemulsions are loaded with siRNA against signal transducer and activator of transcription 3 (STAT3) for combined treatment of lung metastasis in osteosarcoma. Intratracheal instillation of the treatments significantly prolonged the survival of animals with established lung metastases. The treatment with F-PCX@PFC/siSTAT3 emulsion polyplexes decreased the number of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) in the tumors, while increasing CD8(+) T cells infiltration and IFN gamma secretion to overcome the immunosuppressive tumor microenvironment. The reported nanoemulsions represent a promising pulmonary treatment of lung metastatic osteosarcoma.
What problem does this paper attempt to address?